{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:44:50Z","timestamp":1791308690961,"version":"4.3.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40262-024-01452-6","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T08:47:09Z","timestamp":1733215629000},"page":"79-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Population Pharmacokinetic and Toxicity Analysis of High-Dose Methotrexate in Patients with Central Nervous System Lymphoma"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9924-6040","authenticated-orcid":false,"given":"Anyue","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur A.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Nijland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette K.","family":"Doorduijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs Oude","family":"Munnink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda C. M.","family":"de Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena E.","family":"Friberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost S. P.","family":"Vermaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3219-253X","authenticated-orcid":false,"given":"Dirk Jan A. R.","family":"Moes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"issue":"2","key":"1452_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/bloodadvances.2016000927","volume":"1","author":"J Fallah","year":"2016","unstructured":"Fallah J, Qunaj L, Olszewski AJ. Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database. Blood Adv. 2016;1(2):112\u201321. https:\/\/doi.org\/10.1182\/bloodadvances.2016000927.","journal-title":"Blood Adv"},{"issue":"4","key":"1452_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100213","volume":"6","author":"T Calimeri","year":"2021","unstructured":"Calimeri T, Steffanoni S, Gagliardi F, Chiara A, Ferreri AJM. How we treat primary central nervous system lymphoma. ESMO Open. 2021;6(4): 100213. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100213.","journal-title":"ESMO Open."},{"key":"1452_CR3","doi-asserted-by":"publisher","first-page":"1071281","DOI":"10.3389\/fonc.2022.1071281","volume":"12","author":"SY Jeong","year":"2022","unstructured":"Jeong SY, Yoon SE, Cho D, Kang ES, Cho J, Kim WS, et al. Real-world experiences of CNS-directed chemotherapy followed by autologous stem cell transplantation for secondary CNS involvement in relapsed or refractory diffuse large B-cell lymphoma. Front Oncol. 2022;12:1071281. https:\/\/doi.org\/10.3389\/fonc.2022.1071281.","journal-title":"Front Oncol"},{"key":"1452_CR4","unstructured":"Methotrexate Injection [package insert]. HOSPIRA. U.S. Food and Drug Administration. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/011719s125lbl.pdf. Accessed 12 Oct 2022."},{"issue":"1","key":"1452_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2165\/00003495-199447010-00003","volume":"47","author":"B Bannwarth","year":"1994","unstructured":"Bannwarth B, Labat L, Moride Y, Schaeverbeke T. Methotrexate in rheumatoid arthritis. Drugs. 1994;47(1):25\u201350. https:\/\/doi.org\/10.2165\/00003495-199447010-00003.","journal-title":"Drugs"},{"issue":"5","key":"1452_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1365-2141.2009.07765.x","volume":"146","author":"K Schmiegelow","year":"2009","unstructured":"Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol. 2009;146(5):489\u2013503. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07765.x.","journal-title":"Br J Haematol"},{"issue":"12","key":"1452_CR7","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui C-H, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471\u201382. https:\/\/doi.org\/10.1634\/theoncologist.2015-0164.","journal-title":"Oncologist"},{"issue":"2","key":"1452_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/bcp.12326","volume":"78","author":"I Benz-de Bretagne","year":"2014","unstructured":"Benz-de Bretagne I, Zahr N, Le Gouge A, Hulot JS, Houillier C, Hoang-Xuan K, et al. Urinary coproporphyrin I\/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance. Br J Clin Pharmacol. 2014;78(2):329\u201342. https:\/\/doi.org\/10.1111\/bcp.12326.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"1452_CR9","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1080\/10428194.2022.2074987","volume":"63","author":"J Wight","year":"2022","unstructured":"Wight J, Ku M, Garwood M, Carradice D, Lasica M, Keamy L, et al. Toxicity associated with high-dose intravenous methotrexate for hematological malignancies. Leuk Lymphoma. 2022;63(10):2375\u201382. https:\/\/doi.org\/10.1080\/10428194.2022.2074987.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"1452_CR10","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00280-019-03966-4","volume":"84","author":"S Kawakatsu","year":"2019","unstructured":"Kawakatsu S, Nikanjam M, Lin M, Le S, Saunders I, Kuo DJ, et al. Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. Cancer Chemother Pharmacol. 2019;84(6):1339\u201348. https:\/\/doi.org\/10.1007\/s00280-019-03966-4.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1452_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15506","author":"M Ibarra","year":"2022","unstructured":"Ibarra M, Combs R, Taylor ZL, Ramsey LB, Mikkelsen T, Buddington RK, et al. Insights from a pharmacometric analysis of HDMTX in adults with cancer: Clinically relevant covariates for application in precision dosing. Br J Clin Pharmacol. 2022. https:\/\/doi.org\/10.1111\/bcp.15506.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1452_CR12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/sj.bjc.6605559","volume":"102","author":"M Joerger","year":"2010","unstructured":"Joerger M, Huitema AD, Kr\u00e4henb\u00fchl S, Schellens JH, Cerny T, Reni M, et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer. 2010;102(4):673\u20137. https:\/\/doi.org\/10.1038\/sj.bjc.6605559.","journal-title":"Br J Cancer"},{"issue":"3","key":"1452_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/nop\/npad008","volume":"10","author":"JC Zhang","year":"2023","unstructured":"Zhang JC, Stotts MJ, Horton B, Schiff D. Hepatotoxicity from high-dose methotrexate in primary central nervous system lymphoma. Neuro-Oncol Pract. 2023;10(3):291\u2013300. https:\/\/doi.org\/10.1093\/nop\/npad008.","journal-title":"Neuro-Oncol Pract."},{"issue":"4","key":"1452_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/hon.2759","volume":"38","author":"I Amitai","year":"2020","unstructured":"Amitai I, Rozovski U, El-Saleh R, Shimony S, Shepshelovich D, Rozen-Zvi B, et al. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies. Hematol Oncol. 2020;38(4):584\u20138. https:\/\/doi.org\/10.1002\/hon.2759.","journal-title":"Hematol Oncol"},{"issue":"1","key":"1452_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2125.2005.02513.x","volume":"62","author":"M Joerger","year":"2006","unstructured":"Joerger M, Huitema AD, van den Bongard HJ, Baas P, Schornagel JH, Schellens JH, et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol. 2006;62(1):71\u201380. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02513.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1452_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/sj.clpt.6100235","volume":"82","author":"RL Lalonde","year":"2007","unstructured":"Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, et al. Model-based drug development. Clin Pharmacol Ther. 2007;82(1):21\u201332. https:\/\/doi.org\/10.1038\/sj.clpt.6100235.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1452_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1634\/theoncologist.2015-0322","volume":"21","author":"N Buil-Bruna","year":"2016","unstructured":"Buil-Bruna N, Lopez-Picazo JM, Martin-Algarra S, Troconiz IF. Bringing model-based prediction to oncology clinical practice: a review of pharmacometrics principles and applications. Oncologist. 2016;21(2):220\u201332. https:\/\/doi.org\/10.1634\/theoncologist.2015-0322.","journal-title":"Oncologist"},{"issue":"2","key":"1452_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2125.2011.04084.x","volume":"73","author":"M Joerger","year":"2012","unstructured":"Joerger M, Ferreri AJ, Kr\u00e4henb\u00fchl S, Schellens JH, Cerny T, Zucca E, et al. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. Br J Clin Pharmacol. 2012;73(2):240\u20137. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04084.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1452_CR19","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.xphs.2018.01.004","volume":"107","author":"S Mei","year":"2018","unstructured":"Mei S, Li X, Jiang X, Yu K, Lin S, Zhao Z. Population pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma. J Pharm Sci. 2018;107(5):1454\u201360. https:\/\/doi.org\/10.1016\/j.xphs.2018.01.004.","journal-title":"J Pharm Sci"},{"issue":"3","key":"1452_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2125.2010.03712.x","volume":"70","author":"H Blasco","year":"2010","unstructured":"Blasco H, Senecal D, Le Gouge A, Pinard E, Benz-de Bretagne I, Colombat P, et al. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma. Br J Clin Pharmacol. 2010;70(3):367\u201375. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03712.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1452_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s13318-016-0338-1","volume":"42","author":"A Nader","year":"2017","unstructured":"Nader A, Zahran N, Alshammaa A, Altaweel H, Kassem N, Wilby KJ. Population pharmacokinetics of intravenous methotrexate in patients with hematological malignancies: utilization of routine clinical monitoring parameters. Eur J Drug Metab Pharmacokinet. 2017;42(2):221\u20138. https:\/\/doi.org\/10.1007\/s13318-016-0338-1.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"1452_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1186\/s12885-021-08443-x","volume":"21","author":"U Arshad","year":"2021","unstructured":"Arshad U, Taubert M, Seeger-Nukpezah T, Ullah S, Spindeldreier KC, Jaehde U, et al. Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients. BMC Cancer. 2021;21(1):719. https:\/\/doi.org\/10.1186\/s12885-021-08443-x.","journal-title":"BMC Cancer"},{"issue":"6","key":"1452_CR23","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/tpj.2012.37","volume":"13","author":"N Simon","year":"2013","unstructured":"Simon N, Marsot A, Villard E, Choquet S, Khe HX, Zahr N, et al. Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. Pharmacogenom J. 2013;13(6):507\u201313. https:\/\/doi.org\/10.1038\/tpj.2012.37.","journal-title":"Pharmacogenom J."},{"key":"1452_CR24","unstructured":"ARK\u2122 Methotrexate Assay [package insert]. ARK Diagnostics, Inc. 2017. https:\/\/www.ark-tdm.com\/products\/cancer\/methotrexate\/pdfs\/ARK_Methotrexate_Assay_Rev07_August_2017.pdf. Accessed 5 June 2020."},{"issue":"9","key":"1452_CR25","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1452_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.131","volume":"3","author":"RJ Keizer","year":"2015","unstructured":"Keizer RJ, Jansen RS, Rosing H, Thijssen B, Beijnen JH, Schellens JH, et al. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacol Res Perspect. 2015;3(2): e00131. https:\/\/doi.org\/10.1002\/prp2.131.","journal-title":"Pharmacol Res Perspect"},{"issue":"9","key":"1452_CR27","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1023\/a:1011970125687","volume":"15","author":"EN Jonsson","year":"1998","unstructured":"Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res. 1998;15(9):1463\u20138. https:\/\/doi.org\/10.1023\/a:1011970125687.","journal-title":"Pharm Res"},{"key":"1452_CR28","unstructured":"NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [updated November 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"issue":"3","key":"1452_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit\u2013a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241\u201357. https:\/\/doi.org\/10.1016\/j.cmpb.2005.04.005.","journal-title":"Comput Methods Programs Biomed"},{"issue":"2","key":"1452_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/sj.bjc.6601472","volume":"90","author":"AJ Ferreri","year":"2004","unstructured":"Ferreri AJ, Guerra E, Regazzi M, Pasini F, Ambrosetti A, Pivnik A, et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer. 2004;90(2):353\u20138. https:\/\/doi.org\/10.1038\/sj.bjc.6601472.","journal-title":"Br J Cancer"},{"issue":"6","key":"1452_CR31","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1182\/blood-2012-08-452839","volume":"121","author":"LB Ramsey","year":"2013","unstructured":"Ramsey LB, Panetta JC, Smith C, Yang W, Fan Y, Winick NJ, et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 2013;121(6):898\u2013904. https:\/\/doi.org\/10.1182\/blood-2012-08-452839.","journal-title":"Blood"},{"issue":"4","key":"1452_CR32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/phar.2379","volume":"40","author":"MP Pai","year":"2020","unstructured":"Pai MP, Debacker KC, Derstine B, Sullivan J, Su GL, Wang SC. Comparison of body size, morphomics, and kidney function as covariates of high-dose methotrexate clearance in obese adults with primary central nervous system lymphoma. Pharmacotherapy. 2020;40(4):308\u201319. https:\/\/doi.org\/10.1002\/phar.2379.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"1452_CR33","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/Ftd.0000000000000813","volume":"43","author":"F Gallais","year":"2021","unstructured":"Gallais F, Oberic L, Faguer S, Tavitian S, Lafont T, Marsili S, et al. Body surface area dosing of high-dose methotrexate should be reconsidered, particularly in overweight, adult patients. Ther Drug Monit. 2021;43(3):408\u201315. https:\/\/doi.org\/10.1097\/Ftd.0000000000000813.","journal-title":"Ther Drug Monit"},{"issue":"11","key":"1452_CR34","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.6004\/jnccn.2020.7667","volume":"18","author":"M Holdhoff","year":"2020","unstructured":"Holdhoff M, Mrugala MM, Grommes C, Kaley TJ, Swinnen LJ, Perez-Heydrich C, et al. Challenges in the treatment of newly diagnosed and recurrent primary central nervous system lymphoma. J Natl Compr Canc Netw. 2020;18(11):1571\u20138. https:\/\/doi.org\/10.6004\/jnccn.2020.7667.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"1452_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/ftd.0000000000000381","volume":"39","author":"JB Woillard","year":"2017","unstructured":"Woillard JB, Debord J, Benz-de-Bretagne I, Saint-Marcoux F, Turlure P, Girault S, et al. A time-dependent model describes methotrexate elimination and supports dynamic modification of MRP2\/ABCC2 activity. Ther Drug Monit. 2017;39(2):145\u201356. https:\/\/doi.org\/10.1097\/ftd.0000000000000381.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"1452_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF00546719","volume":"26","author":"J Hendel","year":"1984","unstructured":"Hendel J, Nyfors A. Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption. Eur J Clin Pharmacol. 1984;26(1):121\u20134. https:\/\/doi.org\/10.1007\/BF00546719.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"1452_CR37","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s40262-021-00998-z","volume":"60","author":"TC Zwart","year":"2021","unstructured":"Zwart TC, de Vries APJ, Engbers AGJ, Dam RE, van der Boog PJM, Swen JJ, et al. Model-based estimation of iohexol plasma clearance for pragmatic renal function determination in the renal transplantation setting. Clin Pharmacokinet. 2021;60(9):1201\u201315. https:\/\/doi.org\/10.1007\/s40262-021-00998-z.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1452_CR38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","volume":"23","author":"LB Ramsey","year":"2018","unstructured":"Ramsey LB, Balis FM, O\u2019Brien MM, Schmiegelow K, Pauley JL, Bleyer A, et al. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist. 2018;23(1):52\u201361. https:\/\/doi.org\/10.1634\/theoncologist.2017-0243.","journal-title":"Oncologist"},{"issue":"1","key":"1452_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12885-021-09164-x","volume":"22","author":"LR Schaff","year":"2022","unstructured":"Schaff LR, Lobbous M, Carlow D, Schofield R, Gavrilovic IT, Miller AM, et al. Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study. BMC Cancer. 2022;22(1):60. https:\/\/doi.org\/10.1186\/s12885-021-09164-x.","journal-title":"BMC Cancer"},{"issue":"25","key":"1452_CR40","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1200\/JCO.2009.25.4540","volume":"28","author":"BC Widemann","year":"2010","unstructured":"Widemann BC, Balis FM, Kim A, Boron M, Jayaprakash N, Shalabi A, et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol. 2010;28(25):3979\u201386. https:\/\/doi.org\/10.1200\/JCO.2009.25.4540.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1452_CR41","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2217\/pgs.14.97","volume":"15","author":"S Suthandiram","year":"2014","unstructured":"Suthandiram S, Gan GG, Zain SM, Bee PC, Lian LH, Chang KM, et al. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics. 2014;15(11):1479\u201394. https:\/\/doi.org\/10.2217\/pgs.14.97.","journal-title":"Pharmacogenomics"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01452-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01452-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01452-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T04:51:27Z","timestamp":1737780687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01452-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1452"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01452-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"28 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is partially supported by a Madeleine Fellowship and LUMC MD\/PhD stimulation (F.A.d.G and J.S.P.V.)","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article. Daan Touw is an Editorial Board member of Clinical Pharmacokinetics. Daan Touw was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets generated during and\/or analyzed during the current study are not openly available owing to reasons of privacy but are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data"}},{"value":"This study is approved by the local Ethical Committee of each institute (number G20.126) and did not fall within the scope of the WMO (Medical Scientific Research Act). A waiver for informed consent was granted. All performed procedures were in accordance with the ethical standards of the institutional medical ethical committee and the 1964 Declaration of Helsinki and its later amendments.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study is approved by the local Ethical Committee of each institute (number G20.126), and did not fall within the scope of the WMO (Medical Scientific Research Act). A waiver for informed consent was granted.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The population modeling analysis was performed with NONMEM (version 7.4.4, ICON Development Solutions, Ellicott City, MD, USA) aided with Perl-speaks-NONMEM (PsN)\u00a0(version 4.9, Uppsala University, Uppsala, Sweden). Data management and plots generation were performed with R statistics software (version 4.2.1, R Foundation for Statistical Computing, Vienna, Austria).","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Dirk Jan A.R. Moes and Joost S.P. Vermaat contributed to the study conception and design. Fleur A. de Groot, Marcel Nijland, Jeanette K. Doorduijn, Daan J. Touw, Thijs Oude Munnink, Brenda C.M. de Winter, and Anyue Yin contributed to the collection of data. Anyue Yin and Dirk Jan A.R. Moes performed the analysis. Fleur A. de Groot, Lena E. Friberg, Henk-Jan Guchelaar, and Joost S.P. Vermaat contributed to the data analysis and result interpretation. The initial draft of the manuscript was written by Anyue Yin and Dirk Jan A.R. Moes, and all authors commented on the manuscript. All authors reviewed and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}